Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program

Journal of Oncology Pharmacy Practice

Volumn 22, Issue 1, 2016, Pages 68-75

  Deutsch, Sarah ^a   Koerner, Pamela ^b   Miller, Richard T ^a   Craft, Zoie ^a   Fancher, Karen ^b  

^a Walgreens Specialty Pharmacy   (United States)

^b DUQUESNE UNIVERSITY   (United States)

Author keywords

Adherence; Adverse events; Cycle management; Oral chemotherapy; Oral oncology

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; DASATINIB; ERLOTINIB; EVEROLIMUS; NILOTINIB; PAZOPANIB; SORAFENIB; SUNITINIB; VORINOSTAT;

ABDOMINAL PAIN; ADULT; ARTICLE; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL PHARMACY; COUGHING; CUTANEOUS T CELL LYMPHOMA; CYCLE MANAGEMENT PROGRAM; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSPNEA; EVALUATION STUDY; EYE IRRITATION; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; KIDNEY CANCER; LEG PAIN; LEG SWELLING; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; MOUTH PAIN; NAUSEA; ONCOLOGY; PRIORITY JOURNAL; SIDE EFFECT; AGED; MIDDLE AGED; NEOPLASMS; PHARMACIST; PHARMACY; PROCEDURES; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHARMACEUTICAL SERVICES; PHARMACISTS; PHARMACY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84960868095     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214547664     Document Type: Article

References (14)

1. Banna GL, Collva E, Gebbia V, et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev 2010; 36: 595-605.
2. Neuss MN, Polovich M, McNiff K, et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract 2013; 9: 5s-13s.
3. Mancini R, McBride A and Kruczynski M. Oral oncoly-tics: Part 1-Financial, adherence, and management challenges. Oncology 2013; 27: 742-744.
4. Spoelstra S, Given BA, Given CW, et al. An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study. Cancer Nursing 2013; 36: 18-28.
5. Verbrugghe M, Verhaeghe S, Lauwaert K, et al. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 2013; 39: 610-621.
6. Streeter SB, Schwartzberg L, Husain N, et al. Patient and plan characteristics affecting abdaonment of oral oncolytics prescriptions. J Oncol Pract 2011; 7: 46s-51s.
7. [Tarveva®]. Package insert. South San Francisco, CA: Genentech, 2013.
8. Anderson KR, Chambers CR, Lam N, et al. Medication adherence among adults prescribed imatinib, dasatnib, or nilotinib for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract 2014; 20 (in press).
9. Timmers L, Boons C, Kropff F, et al. Adherence and patients' experiences with the use of oral anticancer agents. Acta Oncol 2014; 53: 259-567.
10. Roop J and Wu HS. Current practice patterns of oral chemotherapy results of a national survey. Oncology Nursing Forum December 2013; online publication: A1-A10.
11. Abbott R, Edwards S, Whelan M, et al. Are community pharmacists equipped to ensure safe use of oral antican-cer therapy in the community setting? Results of a crosscountry survey of community pharmacists in Canada. J Oncol Pharm Pract 2014; 20: 29-39.
12. National Library of Medicine. Daily Med. Medication information, including black box warnings for sunitinib, nilotinib, and pazopanib, http://dailymed.nlm.nih.gov (2014, accessed 29 April 2014).
13. National Cancer Institute. Common terminology criteria for adverse events (CTCAE): Version 4.03. U.S. Department of Health and Human Services.
14. Khandelwal N, Duncan I, Ahmed T, et al. Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions. J Natl Compr Canc Netw 2012; 10: 618-625.